TICKERNERD
Menu
STOKSTOKHealthcare · Biotechnology

STOK Stock Forecast: Stoke Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$29
−1.06% on the day

The 14 Wall Street analysts covering Stoke Therapeutics, Inc. hold a median 12-month price target of $44 — +51.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 53 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$1.9B
Ticker Nerd rank
53 / 100
Median analyst target
$44
Analysts covering
14
Revenue$9.3M−32.5% y/y
Operating income−$65.4M
Net income−$61.6M
Free cash flow−$58.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.2%
1M
−11.9%
YTD
−8.5%
1Y
+21.6%
From 52W high
−24.3%
From 52W low
+29.8%
$22
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

STOK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Stoke Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
53 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Accruals
73
Quality
65
Value
61
Volatility
52
Issuance
43
Revisions
43
Size
37
Growth
18

Momentum (90): The shares have been drifting up relative to others.

Growth (18): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

STOK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STOK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26STOKHigh $60Median $44Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $35Median $44High $60

The green dot is the last close — the median target sits +51.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2026JP MorganReinstatesOverweight$40
4 Aug 2026Canaccord GenuityMaintainsBuy$60 → $58
4 Aug 2026Canaccord GenuityMaintainsBuy—
4 Aug 2026Chardan CapitalMaintainsBuy—
4 Aug 2026Chardan CapitalMaintainsBuy$35
4 Aug 2026GuggenheimReiteratesBuy—
4 Aug 2026GuggenheimReiteratesBuy$60
4 Aug 2026WedbushMaintainsOutperform—
4 Aug 2026WedbushMaintainsOutperform$38 → $40
13 July 2026Goldman SachsInitiatesBuy—
13 July 2026Goldman SachsInitiatesBuy$44
11 May 2026BTIGReiteratesBuy—
20 Mar 2026Canaccord GenuityMaintainsBuy—
19 Mar 2026BTIGReiteratesBuy—
18 Mar 2026Chardan CapitalMaintainsBuy—
18 Mar 2026WedbushMaintainsOutperform—
17 Mar 2026NeedhamMaintainsBuy—
17 Mar 2026WedbushMaintainsOutperform—
24 Feb 2026Wolfe ResearchInitiatesOutperform—
12 Jan 2026WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. STOK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

STOK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Stoke Therapeutics, Inc. returned +21.6% against +17.5% for the S&P 500, dividends included.

STOK vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150160Oct 25Jan 26Apr 26Jul 26STOKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STOK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Stoke Therapeutics, Inc. (STOK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
48.8×

Cheaper than 15% of US stocks

Price / sales
67.9×

Cheaper than 5% of US stocks

Price / book
5.2×

Cheaper than 19% of US stocks

EV / EBITDA
−7.1×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
−32.5%

Higher than 8% of US stocks

Earnings growth (YoY)
−32.5%

Higher than 15% of US stocks

Gross margin
—
Operating margin
−701.7%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−61.1%

Higher than 19% of US stocks

Return on assets
−35.9%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Stoke Therapeutics, Inc. (STOK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Stoke Therapeutics, Inc. has a market value of $1.9B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $27.6M. The latest quarter shrank 32.5% year on year.

  • Net income over the same four quarters: −$207.9M, a −753.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$180.7M.

  • Shares outstanding: 62.4M.

  • Trailing P/E: 48.8×; forward P/E: −8.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Stoke Therapeutics, Inc. employs 170 people — $162K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

STOK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
STOKStoke Therapeutics, Inc.$1.9B
53
VIRVir Biotechnology, Inc.$1.8B
94
COAGHemab Therapeutics Holdings, Inc.$1.8B
1
BHVNBiohaven Ltd.$1.8B
30
GHRSGH Research PLC$1.9B
66
ZYMEZymeworks, Inc.$1.9B
77
XNCRXencor, Inc.$1.7B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Stoke Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest STOK news & analysis

Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

Business Wire · 2 Sept 2026neutral

Stoke Therapeutics announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare Conference. The company's lead investigational medicine, zorevunersen, is in development as a potential first-in-class disease-modifying treatment for Dravet syndrome.

Why it matters — STOK watchers would care because the presentation offers exposure and an opportunity for the company to discuss its lead investigational Dravet syndrome candidate, zorevunersen, with the investment community.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire · 18 Aug 2026neutral

Stoke Therapeutics announced that, effective August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven individuals as inducement grants under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement stock-option grants represent a routine equity-compensation action tied to hiring that STOK watchers may track for corporate-governance and share-dilution purposes.

Stoke Therapeutics' Dravet Trial Tops Enrollment Target With Zero Dropouts

MarketBeat · 18 Aug 2026positive

Stoke Therapeutics reported that its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding the target of 150, with no patient discontinuations reported to date.

Why it matters — Strong enrollment and zero dropouts in the pivotal trial suggest steady study progress for a key pipeline candidate in Stoke's development program.

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Seeking Alpha · 5 Aug 2026positive

The article highlights progress on zorevunersen for SCN1A Dravet Syndrome, with an FDA meeting expected in H2 2026, a rolling NDA submission in Q1 2027, and phase 3 EMPEROR data in Q3 2027. It also notes the advancement of STK-002 for autosomal dominant optic atrophy in the phase 1 OSPREY study.

Why it matters — A STOK watcher would care because these upcoming clinical and regulatory milestones for zorevunersen and STK-002 reflect the continued development and broader potential of the company's pipeline.

Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference

Business Wire · 5 Aug 2026neutral

Stoke Therapeutics announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference. The company is developing zorevunersen as a potential disease-modifying treatment for Dravet syndrome.

Why it matters — A STOK watcher would care because the company's leadership is set to present at a major investment conference, offering an opportunity to share updates on its development program.

FAQ

Frequently asked questions about STOK stock

What is the STOK stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Stoke Therapeutics, Inc. have a median 12-month price target of $44, with estimates ranging from $35 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STOK stock a buy right now?

Of the 14 analysts covering Stoke Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stoke Therapeutics, Inc. 53 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STOK?

As at 12 Sept 2026, Stoke Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will STOK stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +51.6% from the last close, and Ticker Nerd's factor model ranks Stoke Therapeutics, Inc. 53 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STOK stock forecast for 2030?

No analyst covering Stoke Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STOK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $60 over the next 12 months.

How has STOK stock performed over the past year?

Stoke Therapeutics, Inc. returned +21.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Stoke Therapeutics, Inc. do?

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases.

What is the latest news on STOK?

The most recent item we track (Business Wire, 2 Sept 2026): "Stoke Therapeutics to Present at the Cantor Global Healthcare Conference". Stoke Therapeutics announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare Conference. The company's lead investigational medicine, zorevunersen, is in development as a potential first-in-class disease-modifying treatment for Dravet syndrome.

Company

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases. Its programs are designed to upregulate protein expression and address the underlying cause of disorders linked to insufficient protein production. The company’s portfolio centers on precision therapies for rare neuromuscular, neurological, and other haploinsufficiency-related conditions, with a strong emphasis on antisense oligonucleotide approaches and targeted gene output modulation. Stoke Therapeutics operates in the genetic medicines and rare disease markets, where its research platform supports the discovery and development of treatments intended to restore healthier levels of naturally occurring proteins. Headquartered in Bedford, Massachusetts, Stoke Therapeutics plays a specialized role in advancing novel therapeutic approaches for patients with complex inherited diseases.

CEO Mr. Ian F. Smith A.C.A., C.P.A. · 170 employees · United States · https://www.stoketherapeutics.com